The relationship between KRAS and PRMT5, therefore, sheds light on a critically important conclusion: the apparent susceptibility of KRAS-mutant CRC cells to PRMT5 inhibition treatment may be used to treat KRAS-mutant CRC in the clinical setting. This evidence concerns the gene KRAS and colorectal carcinoma.